AUS
NZ
UK
CA
USA
IND
Highlights
- FDA approves Mesoblast’s RYONCIL® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy in the U.S.
- RYONCIL becomes the only approved treatment for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.
- Mesoblast shares jump 33% during morning trading hours on December 19.
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), a global leader in allogeneic cellular medicines, saw its shares skyrocket by 33% on December 19 after announcing that the U.S. Food and Drug Administration (FDA) approved its flagship product, RYONCIL® (remestemcel-L). This marks a significant milestone, as RYONCIL becomes the first mesenchymal stromal cell (MSC) therapy approved in the United States for any indication.
Addressing a Critical Medical Need
RYONCIL is now the only approved therapy for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children aged two months and older, including adolescents and teenagers. SR-aGvHD is a severe, life-threatening complication that affects nearly half of the approximately 1,500 pediatric patients who undergo allogeneic bone marrow transplants annually in the United States.
While steroids are the standard first-line treatment for aGvHD, nearly half of the patients fail to respond, highlighting a dire need for alternative therapies. The approval of RYONCIL offers a lifeline to these children, giving them a better chance at survival.
Promising Clinical Results
The FDA’s approval is backed by robust data from a Phase 3 multicenter trial, which included children with severe SR-aGvHD. Key findings from the study include:
- 70% overall response rate by Day 28 of treatment, a metric strongly linked to survival in aGvHD.
- More than 85% of patients completed the full course of treatment without interruption.
- No discontinuation or interruption of treatment due to laboratory abnormalities.
The results, published in Biology of Blood and Marrow Transplantation, underscore the safety and efficacy of RYONCIL in treating a high-risk pediatric population.
A Pioneering Moment for Mesoblast
Commenting on the FDA approval, Mesoblast highlighted the transformational impact of this decision, both for the company and for the field of regenerative medicine. RYONCIL’s approval cements Mesoblast’s position as a global leader in cellular therapies and opens new doors for advancing its pipeline of MSC-based products.
The therapy’s groundbreaking approval not only addresses a significant unmet medical need but also sets a precedent for the use of MSCs in treating other inflammatory diseases.
Market Reaction
Investors celebrated the FDA announcement, pushing Mesoblast’s shares up by 33% during morning trading hours on December 19.
